News
IMGN
31.23
0.00%
0.00
UPDATE 4-Lazard profit beats estimates as dealmaking rebound fuels record revenue
Lazard's first-quarter profit beats estimates as dealmaking rebound fuels record revenue. Firmwide and advisory revenues surged to record levels. The bank advised on a string of high-profile deals in the first quarter. Lazard's adjusted revenue jumped 42% to $747 million.
Reuters · 1d ago
UPDATE 3-Lazard posts better-than-expected profit on deals, assets boost
Lazard posts better-than-expected profit on deals, assets boost in first quarter. Investment bank's adjusted revenue jumped 42% to $747 million. Firm advised on a string of high-profile mergers and acquisitions in the quarter. Lazard's assets under management rose to $250 billion from $232 billion.
Reuters · 1d ago
UPDATE 2-Lazard posts first-quarter profit on deals, assets boost
Lazard posts first-quarter profit on deals, assets boost. Investment bank's profit boosted by a string of high-profile mergers and acquisitions it advised on in the first quarter. Lazard's assets under management rose to $250 billion in the quarter from $232 billion a year earlier.
Reuters · 1d ago
Weekly Report: what happened at IMGN last week (0226-0301)?
Weekly Report · 03/04 09:03
Weekly Report: what happened at IMGN last week (0219-0223)?
Weekly Report · 02/26 09:03
AbbVie plans to offer senior notes to fund Immunogen, Cerevel deals
Seeking Alpha · 02/21 18:26
Weekly Report: what happened at IMGN last week (0212-0216)?
Weekly Report · 02/19 09:03
Immunogen Inc: Securities to be offered to employees in employee benefit plans, post-effective amendments
Press release · 02/13 02:38
Immunogen Inc: Statement of changes in beneficial ownership of securities
Press release · 02/12 22:44
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
NASDAQ · 02/12 14:13
ImmunoGen Finalizes Merger, Amends Operations, and Delists Shares
TipRanks · 02/12 13:21
AbbVie revises Q1 earnings outlook as ImmunoGen deal closes
Healthcare M&A AbbVie revises Q1 earnings outlook as ImmunoGen deal closes Feb. 12, 2024. The company has updated its earnings outlook for the first quarter of 2024 to reflect a dilutive impact related to its acquisition of cancer drugmaker immunoGen. With the completion of the acquisition, immunogen is now part of abbvie.
Seeking Alpha · 02/12 13:14
*Correct: AbbVie Raises 1Q View To Adj EPS $2.30-Adj EPS $2.34 >ABBV
Dow Jones · 02/12 12:50
*AbbVie Raises FY24 View To EPS $2.30-EPS $2.34 >ABBV
Dow Jones · 02/12 12:40
*AbbVie Backs FY24 Adj EPS $11.05-Adj EPS $11.25 >ABBV
Dow Jones · 02/12 12:39
Press Release: AbbVie Completes Acquisition of ImmunoGen
AbbVie adds flagship antibody-drug conjugate ELAHERE for platinum-resistant ovarian cancer to its portfolio. The first and only drug approved by the FDA in ovarian cancer. Abbvie's acquisition of ImmunoGen complements the company's existing oncology pipeline.
Dow Jones · 02/12 12:38
*AbbVie Completes Acquisition Of ImmunoGen >ABBV IMGN
Dow Jones · 02/12 12:38
Weekly Report: what happened at IMGN last week (0205-0209)?
Weekly Report · 02/12 09:03
Barclays Keeps Their Hold Rating on ImmunoGen (IMGN)
Barclays maintains a Hold rating on ImmunoGen (IMGN) with a price target of $31.00. The company’s market cap is currently $8.72B and has a P/E ratio of -104.24. Currently, the analyst consensus on immunoGen is a Hold.
TipRanks · 02/12 08:46
Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means
Seeking Alpha · 02/09 16:24
More
Webull provides a variety of real-time IMGN stock news. You can receive the latest news about Immunogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMGN
ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).